Abstract #1156

Predictive Value of Magnetic Resonance Spectroscopic Imaging during Anti-angiogenic Treatment in Recurrent Glioblastoma

Daniel Kim^1,2, Jorg Dietrich³, Elizabeth Gerstner^2,3, Julian He¹, Otto Rapalino¹, Yangming Ou⁴, Yi-Fen Yen^1,2, Mark Vangel¹, Ovidiu Andronesi^1,2, Isabel Arrillaga³, Deborah Forst³, Jayashree Kalpathy-Cramer ^1,2, Bruce Rosen^1,2, Tracy Batchelor³, Ramon Gilberto Gonzalez¹, and Eva-Maria Ratai^1,2

¹Radiology, Massachusetts General Hospital, Boston, MA, United States, ²Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA, United States, ³Neurology, Massachusetts General Hospital, Boston, MA, United States, ⁴Radiology, Boston Children's Hospital, Boston, MA, United States

Our study examines the use of MR Spectroscopic Imaging to predict treatment response to anti-angiogenic therapy for recurrent glioblastoma patients. Our data demonstrated that early changes at 1-3 days, 4 weeks, and 6 weeks in Cho/NAA, Lac/nCr, and Lac/NAA can be predictive of 9-months survival outcomes in patients with recurrent glioblastoma treated with bevacizumab. Theses preliminary findings suggest that early changes in certain metabolic ratios can be useful markers for predicting therapeutic response to bevacizumab treatment.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.